Galvani Bioelectronics develops implantable bioelectronic therapies designed to modulate nerve signals involved in chronic disease. The company’s approach focuses on interfacing with peripheral nerves that regulate organ function rather than directly targeting the brain. Its platforms are engineered for chronic implantation and long-term therapeutic use. Galvani Bioelectronics positions its technology within regulated clinical development and pharmaceutical collaboration contexts.

The technology delivers targeted electrical stimulation to specific peripheral nerves, such as the splenic nerve, to influence immune and inflammatory pathways. By modulating organ-specific neural signaling, the system aims to alter disease-relevant physiological processes. This bioelectronic approach combines neural interfacing with principles traditionally associated with drug therapy. The implants are designed to operate continuously or under programmable stimulation protocols.

Galvani Bioelectronics targets chronic inflammatory and autoimmune diseases where neural regulation plays a role in disease progression. The platform is intended for use within formal clinical trials and therapeutic development pathways. Its focus reflects growing interest in bioelectronic medicine as a modality for treating systemic disease through precise neural modulation.